Clinical trial
OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study
NCT05104138 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study
- Lead sponsor
- Federico II University
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 1, 2015
- Completion date
- November 30, 2017
- Enrollment
- 30 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.